183735-79-7Relevant academic research and scientific papers
Access to the new isoindolo[1,3]benzothiazocinones via the combination of N-acyliminium chemistry and friedel-crafts type π-cyclization
Cul, Armelle,Daich, Adam,Decroix, Bernard,Sanz, Gerard,Van Hijfte, Luc
, p. 33 - 39 (2007/10/03)
New racemic and chiral [4,2]- and [3,5]benzothiazocines (4) and (5) in the isoindolinone series were synthesized easily in few steps based on the combination of N-acyliminium chemistry and π-cationic cyclization of acylium ions. The chemoselectivity observed during these processes, particularly in the reduction, the thioalkylation and the cyclization stages, were also discussed.
3-Cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: Synthesis and initial structure-activity relationships
Dhar, T. G. Murali,Shen, Zhongqi,Gu, Henry H.,Chen, Ping,Norris, Derek,Watterson, Scott H.,Ballentine, Shelley K.,Fleener, Catherine A.,Rouleau, Katherine A.,Barrish, Joel C.,Townsend, Robert,Hollenbaugh, Diane L.,Iwanowicz, Edwin J.
, p. 3557 - 3560 (2007/10/03)
A series of novel small molecule inhibitors of inosine monophosphate dehydrogenase (IMPDH), based upon a 3-cyanoindole core, were explored. IMPDH catalyzes the rate determining step in guanine nucleotide biosynthesis and is a target for anticancer, immuno
5H, 10H-IMIDAZO[1,2-A]INDENO[1,2-E] PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES
-
, (2008/06/13)
Compounds of formula (I), wherein R is a hydrogen atom or a carboxy, alkoxycarbonyl,--CO--NR 4 R 5,--PO 3 H 2 or--CH 2 OH radical, and R 1 is an-alk-NH 2,-alk-NH--CO--R 3,-alk-COOR 4,-alk-CO--NR 5 R 6 or--CO--NH--R 7 radical. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartame (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.
